Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | AGXT | P21549 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642402 | 0.93 | IDO1 (0.40) | IDO1TSHRTRPA1ALDH1A1TAAR1 | |
| SCHEMBL9616495 | 0.87 | IDO1 (0.38) | IDO1TSHRTRPA1ALDH1A1 | |
| SCHEMBL671058 | 0.81 | IDO1 (0.34) | IDO1TSHRTRPA1ALDH1A1 | |
| SCHEMBL10448080 | 0.81 | IDO1 (0.33) | IDO1TSHRTRPA1ALDH1A1 | |
| SCHEMBL29999249 | 0.81 | TSHR (0.40) | IDO1TSHRTRPA1ALDH1A1CYP3A4 | |
| SCHEMBL24661052 | 0.81 | IDO1 (0.38) | IDO1TSHRTRPA1ALDH1A1TAAR1 | |
| SCHEMBL13973047 | 0.81 | ACHE (0.40) | IDO1TSHRTRPA1ALDH1A1CYP3A4 | |
| SCHEMBL30349373 | 0.81 | TACR1 (0.41) | IDO1TSHRTRPA1ALDH1A1 | |
| SCHEMBL29472374 | 0.81 | IDO1 (0.34) | IDO1TSHRTRPA1ALDH1A1 | |
| SCHEMBL8447346 | 0.81 | IDO1 (0.33) | IDO1TSHRTRPA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067347-A1 | PHAGE PARTICLE COMPLEX, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2025-04-03 | — | — | WO | claimed |
| CN-103943805-A | Lithium ion secondary battery and diaphragm thereof | NINGDE AMPEREX TECHNOLOGY LTD | 2014-07-23 | — | — | CN | claimed |
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4629980-A1 | ANTIMICROBIAL COMPOUNDS | SRI International (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| WO-2025104079-A1 | SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025096300-A1 | NOVEL METHODS FOR THE PREPARATION OF 3-AZABICYLCO[3.1,0]HEXANE-6-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025067347-A1 | PHAGE PARTICLE COMPLEX, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2025-04-03 | — | — | WO | disclosed |
| CN-119490464-A | Preparation method of 1,2, 3-triazole compound and application thereof in antifungal field | 中国人民解放军海军军医大学 | 2025-02-21 | — | — | CN | disclosed |
| CN-114206904-B | Selective BCRP/ABCG2 transporter inhibitors as agents for eliminating resistance to anticancer agents | 格勒诺布尔-阿尔卑斯大学 | 2024-12-03 | — | — | CN | disclosed |
| US-20240295548-A1 | PHOTOAFFINITY PROBES | PROMEGA CORPORATION | 2024-09-05 | — | — | US | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0641333-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0593557-A1 | AROMATIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY. | MERCK SHARP & DOHME (GB) | 1994-04-27 | — | — | EP | disclosed |
| WO-1993023388-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5254683-A | Neurological disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| WO-1993001160-A1 | AROMATIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 1993-01-21 | — | — | WO | disclosed |
| EP-0522808-A2 | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy | MERCK SHARP & DOHME LTD. (GB) | 1993-01-13 | — | — | EP | disclosed |
| EP-0517876-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS. | ICI PLC (GB) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992011854-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | IDO2, IDO1, BCR | IDO1 2/4885TSHR 3812/4885TRPA1 3799/4885 |
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BCL6, CLTB, MET | IDO1 3561/4885TSHR 1278/4885TRPA1 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.